AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,821,155 | -12.6% | 73,582 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $2,083,842 | +23.3% | 73,582 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,690,179 | -18.2% | 73,582 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $2,066,183 | -0.7% | 73,582 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $2,080,000 | +27.5% | 73,560 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,631,000 | -23.8% | 73,560 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $2,141,000 | -11.2% | 73,560 | +0.3% | 0.00% | 0.0% |
| Q4 2021 | $2,411,000 | -28.8% | 73,360 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,386,000 | -16.9% | 73,360 | -0.8% | 0.00% | -50.0% |
| Q2 2021 | $4,076,000 | +149.4% | 73,960 | +133.7% | 0.00% | +100.0% |
| Q1 2021 | $1,634,000 | -43.8% | 31,642 | -52.8% | 0.00% | 0.0% |
| Q4 2020 | $2,905,000 | -26.6% | 67,042 | -40.7% | 0.00% | -50.0% |
| Q3 2020 | $3,958,000 | -10.5% | 113,094 | +36.9% | 0.00% | -33.3% |
| Q2 2020 | $4,420,000 | +31.6% | 82,640 | -12.7% | 0.00% | +50.0% |
| Q1 2020 | $3,358,000 | +157.7% | 94,652 | +246.8% | 0.00% | +100.0% |
| Q4 2019 | $1,303,000 | -72.2% | 27,292 | -81.1% | 0.00% | -66.7% |
| Q3 2019 | $4,682,000 | +283.1% | 144,492 | +490.0% | 0.00% | +200.0% |
| Q2 2019 | $1,222,000 | -58.0% | 24,492 | -43.2% | 0.00% | -50.0% |
| Q1 2019 | $2,907,000 | +166.5% | 43,112 | +82.2% | 0.00% | +100.0% |
| Q4 2018 | $1,091,000 | -41.4% | 23,662 | -2.1% | 0.00% | 0.0% |
| Q3 2018 | $1,863,000 | -10.3% | 24,162 | -2.1% | 0.00% | 0.0% |
| Q2 2018 | $2,078,000 | +9.4% | 24,672 | +6.2% | 0.00% | 0.0% |
| Q1 2018 | $1,899,000 | +53.5% | 23,222 | +7.3% | 0.00% | 0.0% |
| Q4 2017 | $1,237,000 | -45.2% | 21,642 | -36.0% | 0.00% | -50.0% |
| Q3 2017 | $2,256,000 | +101.6% | 33,792 | +55.4% | 0.00% | +100.0% |
| Q2 2017 | $1,119,000 | +2.5% | 21,742 | +16.3% | 0.00% | 0.0% |
| Q1 2017 | $1,092,000 | +40.0% | 18,692 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $780,000 | -18.2% | 18,692 | +3.6% | 0.00% | 0.0% |
| Q3 2016 | $953,000 | +26.1% | 18,050 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $756,000 | +109.4% | 18,050 | +102.8% | 0.00% | – |
| Q1 2016 | $361,000 | -38.6% | 8,900 | -1.8% | 0.00% | -100.0% |
| Q4 2015 | $588,000 | -97.4% | 9,060 | -97.2% | 0.00% | -95.0% |
| Q3 2015 | $22,972,000 | -37.0% | 325,434 | -0.8% | 0.02% | -33.3% |
| Q2 2015 | $36,456,000 | +13.8% | 328,022 | -3.4% | 0.03% | +15.4% |
| Q1 2015 | $32,027,000 | +13.3% | 339,625 | +34.7% | 0.03% | +13.0% |
| Q4 2014 | $28,258,000 | +1885.8% | 252,214 | +987.1% | 0.02% | +2200.0% |
| Q3 2014 | $1,423,000 | -0.5% | 23,200 | -25.6% | 0.00% | 0.0% |
| Q2 2014 | $1,430,000 | +1374.2% | 31,200 | +1163.2% | 0.00% | – |
| Q1 2014 | $97,000 | -27.1% | 2,470 | -55.7% | 0.00% | – |
| Q4 2013 | $133,000 | +6550.0% | 5,570 | +7857.1% | 0.00% | – |
| Q3 2013 | $2,000 | – | 70 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |